GAITHERSBURG, Md., May 30, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the company will be participating in the following conferences:

  • Jefferies 2018 Healthcare Conference in New York City. Scott Carmer, Chief Executive Officer will be presenting a company update;
  • 2018 BIO International Convention in Boston. Kristi Jones, Chief Operating Officer, will attend and host 1x1 meetings and partnering discussions.

About NexImmune
NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to generate highly targeted T cell-based immunotherapies.  In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system.  For more information visit: www.neximmune.com

Contact
Chad Rubin
Solebury Trout
+1 (646) 378-2947
crubin@troutgroup.com